Humana
HUM
$396.51
-1.92%
Humana Inc. is one of the largest private health insurers in the United States, operating a niche franchise concentrated in government-sponsored programs, with nearly all medical membership stemming from Medicare, Medicare Advantage, Medicaid, and the military's Tricare program, complemented by a growing healthcare services arm (CenterWell) spanning primary care, home health, and pharmacy benefit management. The company is distinct as the purest-play Medicare Advantage insurer among large-cap managed care peers, making its fortunes unusually sensitive to CMS reimbursement policy, risk-adjustment coding trends, and senior utilization patterns rather than commercial group insurance cycles. The current investor narrative is dominated by a dramatic profitability turnaround: after a deeply loss-making 2025 — including a Q4 2025 net loss of $796 million and negative EBITDA of $685 million — Humana has returned to solid profitability in the first half of 2026, with Q2 2026 net income of $693 million and revenue growth of 26.2% year over year. Sentiment has been further supported by a larger-than-expected 2027 Medicare Advantage rate increase from CMS (announced April 2026) that lifted the entire managed care sector, and by strategic M&A interest in assets such as MaxHealth, while analysts continue to debate the sustainability of margin recovery given elevated medical cost trends and a still-negative trailing free cash flow profile.…
HUM
Humana
$396.51
Related headlines
Investment Opinion: Should I buy HUM Today?
Based on the synthesis of fundamental, valuation, and analyst data, the recommendation is a Hold with a bias toward accumulating on weakness. The core thesis is that Humana is in the midst of a credible earnings recovery, but the current valuation already reflects much of the near-term upside, and significant risks remain. The analyst consensus rating of 2.15 (buy) and average target price of $423.74 imply only 9.1% upside, suggesting the stock is fairly valued after its 118% six-month rally. The company's revenue growth of 26.18% and swing to profitability are impressive, but the negative free cash flow and thin margins warrant caution.
Supporting evidence for the Hold rating includes: 1) Revenue growth of 26.18% year-over-year in Q2 2026, well above sector norms; 2) A return to profitability with Q2 2026 net income of $693 million and Q1 2026 net income of $1.186 billion; 3) A favorable CMS rate environment for 2027 that provides revenue visibility; and 4) Analyst targets ranging from $280 to $515, with an average of $423.74. However, the forward PE of 23.41x is a premium to the stock's historical range, and the PEG ratio is not meaningful due to the depressed trailing earnings base. The price-to-book ratio of 1.75x is near historical lows, but this is offset by the negative free cash flow and high debt-to-equity of 0.733.
The biggest risks that could invalidate the thesis are: 1) A deterioration in medical cost trends that compresses margins further; 2) Unfavorable CMS rate updates for 2028 and beyond; and 3) A failure to generate positive free cash flow, which could pressure the dividend. The rating would upgrade to Buy if the forward PE compresses below 18x while revenue growth remains above 20%, or if free cash flow turns sustainably positive. It would downgrade to Sell if operating margins fall below 1% or if revenue growth decelerates below 10%. Relative to its own history and peers, Humana appears fairly valued on earnings but potentially undervalued on book value and sales, assuming the margin recovery materializes.
Sign up to view all
HUM 12-Month Price Forecast
Humana presents a compelling recovery story with strong revenue growth and a return to profitability, but the valuation already reflects much of the near-term optimism. The stock's 118% six-month rally has been driven by idiosyncratic factors like CMS rate updates and earnings beats, but the sustainability of margin recovery is uncertain given negative free cash flow and thin operating margins. The analyst consensus is cautiously bullish, but the modest upside to the average target and wide target range suggest limited conviction. I would upgrade to bullish if the company demonstrates two consecutive quarters of positive free cash flow and operating margin expansion above 3%. I would downgrade to bearish if medical cost trends accelerate or if CMS announces unfavorable 2028 rates, which could trigger a sharp re-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $423.74 and implied upside of +6.9% versus the current price.
Average Target
$423.74
0 analysts
Implied Upside
+6.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $515
Analyst target range
Humana is covered by 23 analysts, and the consensus recommendation is "buy" with a recommendation mean of 2.15 (on a scale where 1 is a strong buy and 5 is a strong sell), indicating a moderately bullish but not overwhelmingly enthusiastic stance. The average price target is $423.74, which implies approximately 9.1% upside from the current price of $388.36 — a modest expected return that suggests analysts see the stock as fairly valued to slightly undervalued after its massive run. The consensus leans cautiously bullish: the buy rating is supported by the earnings recovery and favorable CMS rate environment, but the relatively small implied upside and the 2.15 recommendation mean (which sits between "buy" and "hold") indicate that many analysts are waiting for more evidence of sustainable margin improvement before turning more constructive. The distribution of ratings is mixed, with recent actions showing both upgrades and downgrades: Barclays upgraded to Overweight from Equal Weight on September 25, 2026, Morgan Stanley upgraded to Equal Weight from Underweight on August 5, 2026, and Evercore ISI upgraded to Outperform from In Line on July 30, 2026, while Raymond James downgraded to Market Perform from Outperform on July 30, 2026 — a pattern that suggests analysts are becoming more constructive on the recovery but remain divided on the pace and durability of the turnaround. The target price range is wide, from a low of $280 to a high of $515, a spread of $235 (or 84% of the low target), which signals significant disagreement about the company's future earnings power and medical cost trajectory. The high target of $515 implies roughly 32.6% upside from the current price and likely assumes successful execution on margin recovery, favorable finalization of 2027 CMS rates, and multiple expansion as earnings normalize — essentially a "bull case" where Humana returns to mid-single-digit net margins. The low target of $280 implies roughly 27.9% downside and likely prices in a scenario where medical costs remain elevated, CMS rates disappoint, and the company fails to achieve the margin recovery that the market is currently anticipating. The wide spread, combined with the recent mix of upgrades and downgrades, suggests that conviction is moderate and that the stock is likely to remain volatile around earnings releases and CMS policy announcements; investors should note that the consensus EPS estimate of $35.53 for the forward period (with a range of $33.59 to $37.43) implies a dramatic earnings recovery that, if achieved, would bring the forward PE down to roughly 10.9x at the current price — a valuation that would look very attractive, but one that is highly dependent on execution.
Bulls vs Bears: HUM Investment Factors
The bull case for Humana rests on a powerful earnings recovery, explosive revenue growth, and a favorable CMS rate environment that disproportionately benefits its Medicare Advantage-focused model. The bear case centers on negative free cash flow, thin margins, and a premium valuation that already prices in a successful turnaround. Currently, the bull evidence appears stronger: the company has swung from a $796 million quarterly loss to over $1.8 billion in combined net income in the first half of 2026, revenue is growing at over 26%, and analysts have recently upgraded the stock. However, the most critical tension is whether the margin recovery is sustainable given elevated medical cost trends and the negative cash flow profile. If Humana can restore its operating margin to historical levels (above 5%), the stock could re-rate significantly; if not, the premium multiple could compress sharply.
Bullish
- Explosive revenue growth: Q2 2026 revenue surged 26.18% year over year to $40.867 billion, following 23.5% growth in Q1 2026. This acceleration is well above the typical single-digit growth for large-cap managed care peers, driven by Medicare Advantage membership gains and favorable CMS rate updates.
- Dramatic profitability turnaround: After a Q4 2025 net loss of $796 million, Humana returned to profitability with Q1 2026 net income of $1.186 billion and Q2 2026 net income of $693 million. This swing demonstrates the company's ability to rapidly adjust to changing medical cost trends and pricing.
- Favorable CMS rate environment: The larger-than-expected 2027 Medicare Advantage rate increase announced in April 2026 provides multi-year revenue visibility and margin support. This policy tailwind benefits Humana disproportionately as the purest-play MA insurer.
- Strong relative price momentum: HUM has outperformed the S&P 500 by 36.33 percentage points over the past year and 33.98 percentage points year-to-date, with a 118.39% gain over six months. This relative strength reflects improving fundamentals and positive sentiment.
Bearish
- Negative free cash flow: Trailing twelve-month free cash flow is -$443 million, and Q2 2026 operating cash flow was -$426 million. The negative cash flow profile raises concerns about the sustainability of the dividend, which has a payout ratio of 36.2% and is currently funded from balance sheet capacity.
- Thin and compressing margins: Q2 2026 gross margin fell to 13.45% from 14.98% in Q1 2026 and 14.89% in Q2 2025. The operating margin of 1.12% (TTM) and net margin of 0.92% are well below historical norms, indicating that profitability remains fragile.
- Premium valuation vs. history: The forward PE of 23.41x is above the stock's historical range of 12-18x and the sector's typical mid-to-high teens. This premium leaves little room for error, especially given the wide analyst target range of $280 to $515.
- Liquidity and leverage concerns: The current ratio of 0.724 indicates current liabilities exceed current assets, and debt-to-equity stands at 0.733. While typical for insurers, the combination with negative free cash flow creates financial flexibility risk.
HUM Technical Analysis
Humana is in a powerful recovery uptrend that has more than recovered its prior drawdown: the stock is up 51.34% over the past year and 46.84% year to date, versus the S&P 500's 15.01% and 12.86% respective gains, delivering relative strength of +36.33% over one year and +33.98% YTD. At the current price of $388.36, the shares sit at roughly 90.5% of the 52-week range (low $163.11, high $428.88), meaning the stock is trading in the upper decile of its annual band — a positioning that reflects strong momentum but also leaves limited cushion before overhead resistance and raises the risk of profit-taking after such a steep advance. Notably, the 6-month change of +118.39% dwarfs the 1-year gain, indicating that the bulk of the move occurred in the last two quarters and that the trend is still relatively young rather than a mature, multi-year advance. Short-term momentum, however, has cooled: the stock is down 3.14% over the past month and 2.11% over three months, diverging sharply from the +118.39% six-month surge and underperforming SPY by 3.73 and 5.45 percentage points over those windows, respectively. This divergence between a strong 6-month/1-year trend and negative 1-month/3-month performance suggests a consolidation or digestion phase rather than a trend reversal, particularly since the pullback from the September high of $409.80 has been orderly and the stock bounced 2.29% on the most recent session. With a short ratio of 3.03 and average volume of roughly 765,000 shares, there is no evidence of aggressive short-side pressure, and the recent choppy action between roughly $372 and $410 looks like a classic high-level base-building pattern after a parabolic run. Key technical levels are well defined: support rests at the 52-week low of $163.11 (a level now 58% below the current price and effectively a disaster scenario), with more relevant near-term support around the September swing low of $372 and the $360–$365 zone that contained the July pullback; resistance sits at the 52-week high of $428.88, roughly 10.4% above the current price. A decisive breakout above $428.88 would confirm the resumption of the primary uptrend and likely open a new leg higher, while a breakdown below $360 would signal that the recovery trade is losing steam and could expose the stock to a deeper mean-reversion toward the $320–$330 area where it consolidated in June. Volatility is a critical consideration: with a beta of 0.745, Humana is roughly 25% less volatile than the broader market, which is unusual for a stock that has nearly doubled in six months and suggests the recent price action is driven by idiosyncratic fundamental news (earnings, CMS rates) rather than broad market beta — a profile that favors position sizing based on event risk rather than index correlation, though the trailing max drawdown of -47.54% is a stark reminder of how violently this name can re-rate when Medicare Advantage fundamentals deteriorate.
Beta
0.74
0.74x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+34.3%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | -1.3% | +0.9% |
| 3m | -0.3% | +3.4% |
| 6m | +106.4% | +14.4% |
| 1y | +34.3% | +16.2% |
| ytd | +49.9% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory has re-accelerated dramatically: Q2 2026 revenue reached $40.867 billion, up 26.18% year over year from $32.388 billion in Q2 2025, following Q1 2026 revenue of $39.648 billion (up 23.5% from $32.112 billion in Q1 2025). The sequential progression from $32.515 billion in Q4 2025 to $39.648 billion in Q1 2026 and $40.867 billion in Q2 2026 shows both strong organic growth and the impact of the CMS rate environment and membership mix. Segment data shows the Insurance business generating $39.14 billion and CenterWell contributing $6.79 billion, offset by $5.063 billion in eliminations/corporate, confirming that the core insurance franchise remains the dominant revenue engine while CenterWell provides a vertically integrated growth lever. The key question for investors is whether this revenue acceleration is translating into durable earnings power, since top-line growth in managed care is meaningless if medical costs rise faster — and the Q2 2026 gross margin of 13.45% versus Q1 2026's 14.98% and Q2 2025's 14.89% suggests some margin give-back even as revenue surged. Profitability has swung decisively back into positive territory after a brutal 2025: Q2 2026 net income was $693 million (net margin 1.70%) and Q1 2026 net income was $1.186 billion (net margin 2.99%), a sharp reversal from the Q4 2025 net loss of $796 million (net margin -2.45%) and the Q3 2025 net income of just $195 million (net margin 0.60%). Gross margin, however, is compressing on a sequential basis — 13.45% in Q2 2026 versus 14.98% in Q1 2026 and 14.89% in Q2 2025 — and the operating margin of just 1.12% (TTM) remains thin for a company of this scale, reflecting the low-margin nature of government-sponsored insurance. The company's net margin of 0.92% and operating margin of 1.12% are well below what Humana historically earned (Q1 2025 operating margin was 5.13%), indicating that while the company is profitable again, it is operating at a fraction of its normalized earnings power, and the market is effectively pricing in a multi-year margin recovery rather than a return to peak profitability. The balance sheet and cash flow picture is the most concerning element of the fundamental story: trailing twelve-month free cash flow is -$443 million, Q2 2026 operating cash flow was -$426 million with free cash flow of -$558 million, and the current ratio of 0.724 indicates that current liabilities exceed current assets — a liquidity profile that would be alarming for most companies but is somewhat typical for insurers that hold investments in non-current buckets. Debt-to-equity stands at 0.733, which is manageable but not conservative, and with ROE of just 6.73% and ROA of 3.90%, the company is generating subpar returns on capital relative to its cost of equity. The Q1 2026 quarter did generate $1.254 billion in operating cash flow and $1.133 billion in free cash flow, demonstrating that cash generation is highly seasonal and can be strong when medical costs are controlled, but the Q2 reversal to negative operating cash flow (-$426 million) driven by a $2.177 billion working capital drain (including a $2.724 billion payables swing) highlights the fragility of the cash flow profile. With a dividend payout ratio of 36.2% and a dividend yield of 1.39%, the company is returning cash to shareholders, but the negative TTM free cash flow means this dividend is currently being funded from balance sheet capacity rather than organic cash generation — a dynamic that must reverse for the investment case to hold.
Quarterly Revenue
$40.9B
2026-06
Revenue YoY Growth
+26.2%
YoY Comparison
Gross Margin
13.5%
Latest Quarter
Free Cash Flow
$-443000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Because Humana is profitable on a trailing basis (TTM net income is positive, with Q2 2026 EPS of $5.79 and Q1 2026 EPS of $9.85), the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 25.95x and a forward PE of 23.41x, and the relatively modest gap between the two (roughly 10%) implies that the market expects only moderate earnings growth over the next twelve months — a somewhat surprising read given that consensus estimated EPS of $35.53 for the forward period would represent a massive recovery from the depressed trailing earnings base. The trailing PE is inflated by the low trailing earnings (TTM EPS of just $0.039), so the forward PE of 23.41x is the more meaningful figure, and it places Humana at a premium to the broader market and to many value-oriented healthcare names, reflecting the market's confidence in the earnings recovery. On a price-to-sales basis, Humana trades at just 0.238x — extraordinarily low in absolute terms — but this is typical for health insurers, which operate on thin margins and high revenue volumes; the EV/Sales of 0.251x and EV/EBITDA of 13.61x provide a more complete picture, with the EV/EBITDA multiple suggesting the company is valued at a moderate premium to its asset-light earnings power. The PEG ratio of -18.55 is not meaningful given the negative trailing earnings base, and the price-to-book of 1.75x is reasonable for a company with 6.73% ROE, though it implies the market is paying a modest premium to book for a business that is only marginally profitable on a trailing basis. Peer comparison is challenging because the valuation data provided does not include explicit industry average multiples, but context from the managed care sector is instructive: Humana's forward PE of 23.41x is above the sector's typical range of mid-to-high teens for large-cap diversified insurers, reflecting Humana's pure-play Medicare Advantage exposure and the market's expectation of outsized earnings recovery. The premium is arguably justified by the company's 26.18% revenue growth (well above the sector norm) and the potential for significant margin expansion as Medicare Advantage rates improve, but it also leaves little room for error — any disappointment in medical cost trends or CMS rate finalization could compress the multiple sharply. On a price-to-sales basis, Humana's 0.238x is at the low end of its historical range, which is a function of both the revenue surge (denominator effect) and the depressed earnings, and investors should be cautious about reading too much into this metric for a low-margin insurer. Historical ratio data shows a dramatic compression in valuation multiples over the past two years: the PE ratio was 14.33x in Q1 2024 and 16.56x in Q2 2024, fell to negative territory in Q4 2024 and Q4 2025 due to losses, and has now recovered to 25.95x on a trailing basis — but the forward PE of 23.41x is still below the 2023 levels when the stock traded at 12–18x earnings with much stronger profitability. The price-to-book ratio of 1.75x is near the low end of its historical range (it was 3.66x in Q1 2023 and 2.70x in Q2 2024), suggesting that on a book value basis the stock is not expensive relative to its own history, but the PS ratio of 0.238x is at an all-time low for the company, reflecting the massive revenue base expansion. The key takeaway is that Humana's valuation is a tale of two metrics: on earnings-based measures it looks moderately expensive relative to its own history, but on book value and sales it looks cheap — and the resolution of this discrepancy depends entirely on whether the company can restore its margins to historical norms, which would cause the PE to compress rapidly as earnings normalize.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's trailing twelve-month free cash flow is -$443 million, and Q2 2026 alone saw a $558 million free cash flow deficit, driven by a $2.177 billion working capital drain. This negative cash flow, combined with a current ratio of 0.724 and a dividend payout ratio of 36.2%, raises questions about the sustainability of shareholder returns without balance sheet strain. Additionally, the operating margin of 1.12% (TTM) is razor-thin, and the Q2 2026 gross margin of 13.45% declined both sequentially and year-over-year, indicating that medical cost trends remain a persistent headwind. With ROE of just 6.73% and ROA of 3.90%, the company is generating subpar returns relative to its cost of capital, and any further margin erosion could quickly return it to losses.
Market and competitive risks are equally concerning. Humana trades at a forward PE of 23.41x, a premium to its historical range of 12-18x and to many diversified managed care peers, leaving it vulnerable to multiple compression if growth or margin recovery disappoints. The stock's beta of 0.745 suggests lower volatility than the market, but its trailing max drawdown of -47.54% demonstrates how violently it can re-rate on adverse news. Competitive pressures from larger, more diversified insurers like UnitedHealth and CVS Health, which have broader revenue bases and greater negotiating leverage, could limit Humana's pricing power. Regulatory risk is ever-present: while the 2027 CMS rate increase was favorable, future rate updates or changes to risk-adjustment coding practices could negatively impact revenue and margins. Recent news highlights sector-wide enthusiasm, but also underscores the dependence on government policy.
The worst-case scenario would involve a combination of factors: medical costs continue to rise faster than premiums, CMS implements unfavorable rate changes for 2028, and the company fails to achieve the margin recovery priced into the stock. In this scenario, Humana could retest its 52-week low of $163.11, representing a 58% decline from the current price of $388.36. The analyst low target of $280 implies a 27.9% downside, but a more severe outcome could see the stock fall to the $200-$250 range if operating margins remain below 2% and free cash flow stays negative. Investors could lose 35-50% of their capital in such an adverse scenario, especially if the dividend is cut or the company requires external financing.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of -$443 million TTM and a current ratio of 0.724, which could pressure the dividend. 2) Margin risk: gross margin declined to 13.45% in Q2 2026 from 14.89% a year ago, and operating margin is only 1.12%, leaving little buffer. 3) Regulatory risk: dependence on CMS rate updates, with the 2028 announcement a major unknown. 4) Competitive risk: larger, more diversified peers like UnitedHealth and CVS Health may have greater pricing power. 5) Valuation risk: the forward PE of 23.41x is a premium that could compress if growth slows. These risks are ranked from most to least severe, with financial and margin risks being the most immediate.
The 12-month forecast includes three scenarios: bull case (25% probability) with a target range of $480-$515, base case (55% probability) with a target range of $400-$450, and bear case (20% probability) with a target range of $280-$320. The base case is most likely, assuming revenue growth moderates to the mid-teens and operating margins improve gradually to 2-3%. The key assumption is that medical cost trends remain stable and CMS rates are implemented as expected. The analyst average target of $423.74 aligns with the base case, implying 9.1% upside from the current price.
Humana appears fairly valued to slightly overvalued on earnings-based metrics. The forward PE of 23.41x is above the stock's historical range of 12-18x and the sector's typical mid-to-high teens, reflecting the market's expectation of a strong earnings recovery. However, on a price-to-book basis, the stock trades at 1.75x, near the low end of its historical range, and the price-to-sales ratio of 0.238x is at an all-time low. This discrepancy suggests that if the company can restore its margins to historical norms, the earnings multiple would compress rapidly, making the stock look cheap. The market is currently pricing in a successful turnaround, leaving little room for disappointment.
Humana is a good buy for investors who believe in the company's margin recovery story and are willing to accept above-average risk. The stock has rallied 118% over six months, and the analyst average target of $423.74 implies 9.1% upside, which is modest. However, the high target of $515 suggests 32.6% upside if the bull case materializes. The biggest downside risk is a retest of the 52-week low of $163.11, representing 58% downside, though the analyst low target of $280 implies a more moderate 27.9% decline. Given the negative free cash flow and premium valuation, it is best suited for investors with a long-term horizon who can tolerate volatility.
Humana is more suitable for long-term investment (minimum 2-3 years) given its turnaround nature and the multi-year margin recovery story. The stock's beta of 0.745 suggests lower volatility than the market, but its max drawdown of -47.54% shows it can be volatile during periods of fundamental uncertainty. The dividend yield of 1.39% is modest, and the payout ratio of 36.2% is sustainable only if free cash flow turns positive. Short-term trading would require active monitoring of quarterly earnings and CMS announcements, which can cause significant price swings. A long-term holding period allows investors to benefit from the demographic tailwind of aging baby boomers and the potential for margin normalization.